Clinical trials: Small Pox
18-42 Year Old Healthy Vaccinia-naïve Subjects
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
To demonstrate the efficacy of MVA-BN® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody response and by showing that vaccination prior to administration of ACAM2000® results in an attenuated take.
- Trial name
- NCT01913353
- Testing
- MVA BN®, ACAM2000®
- Where
- South Korea
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Myopericarditis, Small Pox
Assessment of Myocarditis After Replication-Deficient Smallpox Immunization
This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA.
- Trial name
- PAMARDSI (NCT05513313)
- Testing
- JYNNEOS
- Volunteers
- 2,350 people, healthy volunteers welcome
- Sponsor
- Womack Army Medical Center
Smallpox
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects
A randomized, double-blind, placebo-controlled Phase III trial to evaluate immunogenicity and safety of three consecutive production lots of IMVAMUNE® (MVA-BN®) smallpox vaccine in healthy, vaccinia-naïve subjects.
- Trial name
- NCT01144637
- Testing
- IMVAMUNE®
- Where
- 34 sites in United States
- Volunteers
- 4,005 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Smallpox
Safety and Efficacy of CJ-50300 in Healthy Volunteers
The currently available stock of smallpox vaccine would be insufficient in the face of an incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are urgently needed because previous manufacturing…
- Trial name
- NCT00607243
- Testing
- smallpox vaccine CJ-50300
- Where
- South Korea
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Non-melanoma Skin Cancer, Basal Cell Carcinoma
Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer
This study examines the safety and efficacy of using the Imvamune smallpox vaccine in the treatment of non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma).
- Conditions
- Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- MUSIC-01 (NCT04410874)
- Testing
- Imvamune
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Ivan Litvinov
Smallpox
High Dose IMVAMUNE® in Vaccinia-Naive Individuals
The purpose of this research is to compare the ability of a new investigational smallpox vaccine called IMVAMUNE® to produce a strong immune response against smallpox disease if given as one single, higher dose compared with two…
- Trial name
- NCT00879762
- Testing
- MVA Smallpox Vaccine
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
To determine the physiological and immunological responses in healthy HIV seronegative adult volunteers vaccinated with a) the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV and b) the Wyeth smallpox…
- Trial name
- NCT00002261
- Testing
- Smallpox Vaccine, HIVAC-1e, gp160 Vaccine (MicroGeneSys)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Smallpox
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
A phase 2 study to assess the MVA smallpox vaccine in previously vaccinated and vaccine- naive subjects at three dose levels.
- Trial name
- NCT00466245
- Testing
- MVA Smallpox vaccine
- Volunteers
- 590 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company